Merits and pitfalls of genetic testing in a hypertrophic cardiomyopathy clinic

• Published in: The Israel Medical Association journal 2014-11, Vol.16 (11), p.707-713
• Main Authors: Arad, Michael, Monserrat, Lorenzo, Haron-Khun, Shiraz, Seidman, Jonathan G, Seidman, Christine E, Arbustini, Eloisa, Glikson, Michael, Freimark, Dov
• Format: Article
• Language: English
• Subjects: Age of Onset; Cardiomyopathy, Hypertrophic - complications; Cardiomyopathy, Hypertrophic - diagnosis; Cardiomyopathy, Hypertrophic - epidemiology; Cardiomyopathy, Hypertrophic - genetics; Cardiomyopathy, Hypertrophic - psychology; Cardiomyopathy, Hypertrophic - therapy; Death, Sudden, Cardiac - etiology; Death, Sudden, Cardiac - prevention & control; Disease Management; Family Health; Female; Genetic Carrier Screening; Genetic Counseling - psychology; Genetic Counseling - statistics & numerical data; Genetic Testing - methods; Genetic Testing - statistics & numerical data; Heart Failure - etiology; Heart Failure - prevention & control; Humans; Israel - epidemiology; Male; Mutation; Patient Participation - psychology; Pedigree; Risk Assessment
• ISSN: 1565-1088

Hypertrophic cardiomyopathy (HCM) is a familial disease with autosomal dominant inheritance and age-dependent penetrance, caused primarily by mutations of sarcomere genes. Because the clinical variability of HCM is related to its genetic heterogeneity, genetic studies may improve the diagnosis and prognostic evaluation in HCM. To analyze the impact of genetic diagnosis on the clinical management of HCM. Genetic studies were performed for either research or clinical reasons. Once the disease-causing mutation was identified, the management plan was reevaluated. Family members were invited to receive genetic counseling and encouraged to be tested for the mutation. Ten mutations in sarcomere protein genes were identified in 9 probands: 2 novel and 8 previously described. Advanced heart failure or sudden death in a young person prompted the genetic study in 8 of the 9 families. Of 98 relatives available for genotyping, only 53 (54%) agreed to be tested. The compliance was higher in families with sudden death and lower in what appeared to be sporadic HCM or elderly-onset disease. Among the healthy we identified 9 carriers and 19 non-carriers. In 6 individuals the test result resolved an uncertainty about "possible HCM." In several cases the genetic result was also used for family planning and played a role in decisions on cardioverter-defibrillator implantation. Recurrence of a same mutation in different families created an opportunity to apply the information from the literature for risk stratification of individual patients. We suggest that the clinical context determines the indication for genetic testing and interpretation of the results.